These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 37481677

  • 1. Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache.
    Wang Y, Yang X, Ji X, Liu M, Zhou C.
    Psychopharmacology (Berl); 2023 Oct; 240(10):2061-2070. PubMed ID: 37481677
    [Abstract] [Full Text] [Related]

  • 2. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
    Davidson JR, Bose A, Korotzer A, Zheng H.
    Depress Anxiety; 2004 Oct; 19(4):234-40. PubMed ID: 15274172
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A.
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [Abstract] [Full Text] [Related]

  • 4. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
    Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R.
    Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [Abstract] [Full Text] [Related]

  • 6. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Apr; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 7. Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
    Allgulander C, Florea I, Huusom AK.
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482
    [Abstract] [Full Text] [Related]

  • 8. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 9. Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study.
    Zirovich MD, Pangarkar SS, Manh C, Chen L, Vangala S, Elashoff DA, Izuchukwu IS.
    Mil Med; 2021 May 03; 186(5-6):493-499. PubMed ID: 33241323
    [Abstract] [Full Text] [Related]

  • 10. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
    Goodman WK, Bose A, Wang Q.
    J Affect Disord; 2005 Aug 03; 87(2-3):161-7. PubMed ID: 15982747
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH, Salinas E.
    J Clin Psychiatry; 2001 Jul 03; 62(7):523-9. PubMed ID: 11488362
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Frontal Secondary Headache Attributed to Supratrochlear and Supraorbital Nerve Entrapment With Oral Medication or Botulinum Toxin Type A vs Endoscopic Decompression Surgery.
    Filipovic B, de Ru JA, Hakim S, van de Langenberg R, Borggreven PA, Lohuis PJFM.
    JAMA Facial Plast Surg; 2018 Sep 01; 20(5):394-400. PubMed ID: 29801115
    [Abstract] [Full Text] [Related]

  • 13. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes.
    Stein DJ, Andersen HF, Goodman WK.
    Ann Clin Psychiatry; 2005 Sep 01; 17(2):71-5. PubMed ID: 16075659
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin A (BoNT/A) for the treatment of depression: A randomized, double-blind, placebo, controlled trial in China.
    Li Y, Zhu T, Shen T, Wu W, Cao J, Sun J, Liu J, Zhou X, Jiang C, Tang Z, Liu T, Chen L, Hu H, Luo W.
    J Affect Disord; 2022 Dec 01; 318():48-53. PubMed ID: 36063974
    [Abstract] [Full Text] [Related]

  • 15. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.
    Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, Andreescu C, Butters MA, Reynolds CF.
    JAMA; 2009 Jan 21; 301(3):295-303. PubMed ID: 19155456
    [Abstract] [Full Text] [Related]

  • 16. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K, Andersen HF, Reines EH.
    Int Clin Psychopharmacol; 2008 Sep 21; 23(5):276-86. PubMed ID: 18703937
    [Abstract] [Full Text] [Related]

  • 17. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
    Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H.
    Int J Neuropsychopharmacol; 2010 Apr 21; 13(3):305-20. PubMed ID: 19691907
    [Abstract] [Full Text] [Related]

  • 18. The safety and efficacy of botulinum toxin A on the treatment of depression.
    Zhang Q, Wu W, Fan Y, Li Y, Liu J, Xu Y, Jiang C, Tang Z, Cao C, Liu T, Chen LH, Hu H, Luo W.
    Brain Behav; 2021 Sep 21; 11(9):e2333. PubMed ID: 34423572
    [Abstract] [Full Text] [Related]

  • 19. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
    Carter NJ, McCormack PL.
    CNS Drugs; 2009 Sep 21; 23(6):523-41. PubMed ID: 19480470
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
    Merideth C, Cutler AJ, She F, Eriksson H.
    Int Clin Psychopharmacol; 2012 Jan 21; 27(1):40-54. PubMed ID: 22045039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.